It boils down to this: drugs are a pretty anti-competitive market, and the US doesn’t have much in the way of opposing rules that would bring prices down. No surprise that companies make more money compared to European countries.
The real question is: if the US stopped allowing this and brought prices under control, would it wreck pharma R&D? People seem to assume the answer is “yes” when they bring up this disparity but I don’t see it being that obvious.
That's what you need to be true for your claim to hold water, not that the overall revenue pool is larger.
https://i.imgur.com/6QOta9X.png
Full source:
https://aspe.hhs.gov/system/files/pdf/259996/ComparisonUSInt...
(The study was done by HHS and was focused on Medicare, which sets prices based on a weighted average of market sales price, including negotiated discounts by insurers.)
Selling your product for 50% more in the US may not be more profitable than selling in EU where your marketing costs are a lot lower.
Of course you’d sell in all markets where you can, but the claim was that US profits > EU profits because US prices > EU prices.
Also, there’s R&D/education that’s really marketing. E.g. advisory panels, grants to the “right” organizations, agencies or researchers
In which case you could kill this stupid marketing budget without much effect on R&D by outlawing drug advertising.
In reality, the established players halve their marketing expense and make it difficult for any upstarts.
Drugs aren't priced relative to what they cost to make or develop any more than airlines price flights based on how much it costs to fly someone between any given city. They're priced at the highest level the market will bear. Is it any surprise that the largest, most powerful economy in the world will bear higher prices? The drugs by definition have higher value because treating someone in a strong economy delivers more marginal value than in other markets. That's math.
Now we can talk about different systems but this is the one being held up today.
CFO: ABC pharma just got FDA approval to sell a generic version of Viagra, our revenue is projected to take a $1.5 billion hit.
CEO: Fuck. Start raising the price of insulin, I gotta hit these wall street estimates.
The issue is government allowing companies to be anti competitive. For example, the government is currently entertaining a lawsuit by one insulin company against another company trying to sell insulin for a lower price. While that lawsuit is ongoing Americans must pay the higher price. Thus really government willing to enforce continued monopoly is one of the problems
[1] https://en.wikipedia.org/wiki/Agricultural_subsidy#United_St...
I know I've set up kind of a straw-man. It might be that the consumer could choose to forgo an expensive drug or medical procedure without fatal consequences, but that's not the interesting case.
Right now insulin is expensive because the government is preventing companies that can produce it for cheaper from selling in the united states because of a lawsuit by the current market holder. That the government even has this power is a textbook example of the danger of governmental interference in the free market. People are literally dying because the government has made the market less free intentionally
Of course, there are competitive markets for both food and insulin in the US. Quoting from a letter to the WSJ yesterday,
> Eli Lilly makes three types of insulin, which in most states you can buy over-the-counter at Wal-Mart for $24 per 1000 unit bottle. One hundred syringes cost $12. I have serious diabetes mellitus and have managed it with Lilly insulin for a decade for under $100 a month.
For some drugs there aren't competitive markets, and in some cases the government prevents competition, but both are typically temporary situations (patents, first-mover advantages) that help to get the drug on the market in the first place. An extortionate price for a drug is better than no access at all, and doubly so when it is going to give way to genuine price competition.
(2) The government doesn't grow food. Sometimes it pays for it, and sometimes it gives people money so they can pay for it, but there isn't a public option in case farmers decide not to sell us beef, because the market works. (But yeah, the government does -- and should -- help people pay for drugs they can't afford when the prices are reasonable.)
(3) Food production is subsidised, but it shouldn't be. And these subsidies have little bearing on the possibility of extortion in the market.
Airlines are a great example of the race to zero profit. Airline margins are slim and thus the cost of travel often reflects exactly the cost of doing the flight itself. JFK to Heathrow requires participation in multiple markets, currency instability, multiple regulators etc which make the cost more excessive. Also london and new York airports are busier than sfo increasing airport fees. Thus in a market with low basically zero margins, the cost from ny to London is more as competitors that cant make the unit economics work leave the market entirely. New competitora cant enter the market at a lower price point because their profit would be zero.
When every manufacturer has their own statin or their own ARB inhibitor, etc., the revenue is split between a true innovator and a bunch of copycats.
Fixing that could allow much more reward for true innovators, at lower prices but profits protected by volume.
The usual problem is that we don’t compare drugs in the same class against each other (for fear of negative results).
In the case of the blood pressure medicine, that process is not possible for the consumer, and as you say, not practiced by the labs. But that doesn’t mean there aren’t a hundred possible pros and cons for one type of molecule versus another to treat XYZ condition in ABC population, with potentially huge variation between patients both explained and unexplained.
There really aren't when comparing different molecules with the same mechanism of action. Individual hospitals and health systems will usually tender out their contracts to the cheapest molecule in each class, or sign up with a buying group that does.
It simplifies prescribing, inventory, distribution and administration too.
Why create more laws and complexity? Why not simply repeal the laws that prohibit importation of drugs and possibly also refuse to enforce private contracts prohibiting reimportation? The reason drugs are cheaper in Canada and Europe than in America is because of American laws that prevent importation.
An analogy: you live in an apartment building in which every other apartment has rent control. Because of this you're going to pay every extra expense for the entire building.
You could decide to become a rent controlled unit as well -- but the building owners would have less money to improve the building, and it would fall into disrepair.
Or, instead, you could try and find a way to get everyone to equitably share the improvements to the building.
And you would know... how?
https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-p...
So what? They clearly believe the marketing helps them make more revenue with the drug; that has nothing to do with covering the cost of R&D.
Your argument would make sense if marketing reduced their ROI, but they clearly believe it does the opposite.
I'm sure developers in San Francisco spend more on housing than on professional/personal development, but that doesn't mean one is precluding the other.
It's only "excess cash" if you assume the ROI on marketing is negative, which is a bold and unsubstantiated claim.
> Also in countries where there’s a public system pharma usually has 0 advertising because people have no choice anyway.
Direct-to-consumer advertising is only one tiny portion of marketing. European pharmaceutical companies spend massive amounts of money on marketing within Europe.
But here's one with unrestricted access [1]: big pharma spends in average 17% of their revenue on R&D, while Apple spends 3%.
[1] https://www.investopedia.com/ask/answers/060115/how-much-dru...
Edit Here's another link that states the average for Big Pharma for 2018 was 20%
[2] https://www.fiercebiotech.com/special-report/top-10-pharma-r...
I think explaining the economic dynamics directly leads to a self evident conclusion: internationally drug prices would increase as US consumers add to demand on foreign markets. Domestic prices would fall for the same reason
Allowing reimportation would do exactly that by increasing (from zero) US demand for drugs from foreign markets.
EDIT: for explaining why.
The reason drugs are cheaper in Canada and Europe is because of the massive negotiating power of a single buyer
OHIP (the government-run insurer in Ontario, to which taxpayers pay the Ontario Health Premium directly) will sometimes pay some or all the cost of some pharmaceuticals in some cases (i.e, antibiotic-corticosteroid ear drops if you are under 25 or over 65, and have been experiencing an ear infection for longer than 30 days) for some classes of people (mostly youth and seniors); but by no means is there a single buyer in Canada, and there isn't one per province either.
I have bought more pharmaceuticals out of pocket in Canada than I have ever been provided during a covered clinic or emergency department visit, and I technically qualify for the youth drug coverage.
The listings for which drugs are covered under what circumstances can be found here: https://www.ontario.ca/page/check-medication-coverage/
Very few countries have single purchasers for pharmaceuticals.
We're not talking about pharmacies; they don't enter the picture here at all.
> If the single payer health plan
Again, almost no country uses a single-payer health plan for pharmaceuticals, so this is isn't relevant.
Read about the raids on generics in India meant for the USA.
They have claimed that but I have my doubts it’s true. It seems more likely that they make good profits outside US and obscene profits in the US. And why should the US subsidize other counties? Maybe we should also pay 200k for a Honda Civic so other countries have cheaper cars?
(Note the first source is data collected together by someone at Pfizer; the second source is a study by an NYU Business School professor. These are public financials, you can run the numbers yourself on Yahoo Finance.)
Nope but no-one dies in the US because they didn't get access to a 7th generation Intel CPU because they got replaced by a 9th generation that's 2% better and twice as expensive.
According to IDC, North America spends $750 billion a year on IT, twice as much as it does on pharmaceuticals. People would save a lot of money if those costs came down. Can we do that by having the government come in and regulate the price of computers and IT contracts? Profits may go down, but that would be okay, because we’d get the same IT products and services for cheaper, right? Why don’t we do that?
We don’t do it because when it comes to less emotionally charged issues, we think clearly. We know that if we did that, talent and capital would leave for greener pastures, and that would compromise innovation.
If the government decided that Internet tech companies were "obscenely profitable" and started regulated prices so profits went down to 10% (instead of 30%+ for some companies like Facebook), do you think Silicon Valley would still produce the same output?
In most European countries, a government regulator fixes the prices with industry. It's not freeloading in that case, they have the choice between negotiating a fair price or not having access to the market at all. And because they're not idiots, they choose to have access to the market.
Most of that money doesn't go to fund R&D and go back to their shareholders anyway :-)
[0] https://www.sciencedirect.com/science/article/pii/S016762961...
No, most marketing is not direct-to-consumer marketing. Marketing absolutely is allowed in Europe, as evidenced by the massive amounts of money that drug companies spend on marketing within Europe.
Separately, the Trump administration is pursuing a regulation that would tie what Medicare pays for drugs administered in doctors’ offices to lower international prices.
Should people in third world countries being excluded from the chance of receiving lifesaving drugs just because they happen to live in a place that isn't as economically successful as the US? Maybe I could be convinced if you pegged the prices to some measure of local purchasing power, but almost any proposal that amounts to poor people not being able to afford medical care in the name of capitalism is verging on immoral in my opinion.
EDIT: It is disappointing that I get downvoted on HN for basically stating the controversial opinion that "people shouldn't die from being poor".
If they are "forced" to sell there, it's only because of two reasons:
1) the US companies started selling there of their own free will, and after their patents expired in those countries, other companies were free to use the formula
2) Other companies would have created the same drugs with or without their patents, and the American companies would've lost all of that market share/brand image in that country. And I bet the competitors would do it for a tiny fraction of the faux R&D costs Big Pharma likes to claim for inventing a new drug.
Besides, the idea that if a company patents something that means it's the only one that could have ever invented that thing needs to die already. The "first to file" patent system that has been adopted in most major countries because of big companies' lobbying is another dead-giveaway that this whole idea is bogus. Why would you have a "first to file" if you didn't have multiple people inventing the same thing at the same time.
Many people or groups of people can come up with the same invention around the world roughly at the same time. Often, those alternatives don't become popular because their papers are in their native tongue and they lack investment, but the "invention" was already made.
If we wanted a system that's more equitable, we could create a law that sets the maximum price for medicine in the US at some multiple of what's charged abroad.
For example: we could say that it's illegal to charge a US person more than 2x what you charge for the drug anywhere else in the world.
This would do two things: it would bring down the cost for US consumers, and it would increase the cost for consumers abroad -- effectively reducing the free-rider effect we currently see in Europe.